Global Pulmonary Embolism Drug 麻豆原创 Research Report 2025

Publication ID:

PB501253203

Publication Date:

January 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Pulmonary Embolism Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pulmonary Embolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Embolism Drug.
The Pulmonary Embolism Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Embolism Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Embolism Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Verseon Corp
Segment by Type
DS-9231
DS-1040
TRX-1
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Embolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Pulmonary Embolism Drug 麻豆原创 Overview
1.1 Product Definition
1.2 Pulmonary Embolism Drug by Type
1.2.1 Global Pulmonary Embolism Drug 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 DS-9231
1.2.3 DS-1040
1.2.4 TRX-1
1.2.5 Others
1.3 Pulmonary Embolism Drug by Application
1.3.1 Global Pulmonary Embolism Drug 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Pulmonary Embolism Drug 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Pulmonary Embolism Drug Revenue 2020-2031
1.4.2 Global Pulmonary Embolism Drug Sales 2020-2031
1.4.3 Global Pulmonary Embolism Drug 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Pulmonary Embolism Drug 麻豆原创 Competition by Manufacturers
2.1 Global Pulmonary Embolism Drug Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Pulmonary Embolism Drug Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Pulmonary Embolism Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application
2.7 Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry
2.8 Global Pulmonary Embolism Drug 麻豆原创 Competitive Situation and Trends
2.8.1 Global Pulmonary Embolism Drug 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Pulmonary Embolism Drug Players 麻豆原创 Share by Revenue
2.8.3 Global Pulmonary Embolism Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pulmonary Embolism Drug 麻豆原创 Scenario by Region
3.1 Global Pulmonary Embolism Drug 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Pulmonary Embolism Drug Sales by Region: 2020-2031
3.2.1 Global Pulmonary Embolism Drug Sales by Region: 2020-2025
3.2.2 Global Pulmonary Embolism Drug Sales by Region: 2026-2031
3.3 Global Pulmonary Embolism Drug Revenue by Region: 2020-2031
3.3.1 Global Pulmonary Embolism Drug Revenue by Region: 2020-2025
3.3.2 Global Pulmonary Embolism Drug Revenue by Region: 2026-2031
3.4 North America Pulmonary Embolism Drug 麻豆原创 Facts & Figures by Country
3.4.1 North America Pulmonary Embolism Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Pulmonary Embolism Drug Sales by Country (2020-2031)
3.4.3 North America Pulmonary Embolism Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pulmonary Embolism Drug 麻豆原创 Facts & Figures by Country
3.5.1 Europe Pulmonary Embolism Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Pulmonary Embolism Drug Sales by Country (2020-2031)
3.5.3 Europe Pulmonary Embolism Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Embolism Drug 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Pulmonary Embolism Drug 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Pulmonary Embolism Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Pulmonary Embolism Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pulmonary Embolism Drug 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Pulmonary Embolism Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Pulmonary Embolism Drug Sales by Country (2020-2031)
3.7.3 Latin America Pulmonary Embolism Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Embolism Drug 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Embolism Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Pulmonary Embolism Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pulmonary Embolism Drug Sales by Type (2020-2031)
4.1.1 Global Pulmonary Embolism Drug Sales by Type (2020-2025)
4.1.2 Global Pulmonary Embolism Drug Sales by Type (2026-2031)
4.1.3 Global Pulmonary Embolism Drug Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Pulmonary Embolism Drug Revenue by Type (2020-2031)
4.2.1 Global Pulmonary Embolism Drug Revenue by Type (2020-2025)
4.2.2 Global Pulmonary Embolism Drug Revenue by Type (2026-2031)
4.2.3 Global Pulmonary Embolism Drug Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Pulmonary Embolism Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Pulmonary Embolism Drug Sales by Application (2020-2031)
5.1.1 Global Pulmonary Embolism Drug Sales by Application (2020-2025)
5.1.2 Global Pulmonary Embolism Drug Sales by Application (2026-2031)
5.1.3 Global Pulmonary Embolism Drug Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Pulmonary Embolism Drug Revenue by Application (2020-2031)
5.2.1 Global Pulmonary Embolism Drug Revenue by Application (2020-2025)
5.2.2 Global Pulmonary Embolism Drug Revenue by Application (2026-2031)
5.2.3 Global Pulmonary Embolism Drug Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Pulmonary Embolism Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Accu-Break Pharmaceuticals, Inc.
6.1.1 Accu-Break Pharmaceuticals, Inc. Company Information
6.1.2 Accu-Break Pharmaceuticals, Inc. Description and Business Overview
6.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio
6.1.5 Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates
6.2 Dong-A Socio Holdings Co. Ltd.
6.2.1 Dong-A Socio Holdings Co. Ltd. Company Information
6.2.2 Dong-A Socio Holdings Co. Ltd. Description and Business Overview
6.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio
6.2.5 Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates
6.3 F. Hoffmann-La Roche Ltd.
6.3.1 F. Hoffmann-La Roche Ltd. Company Information
6.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio
6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.4 Genentech, Inc.
6.4.1 Genentech, Inc. Company Information
6.4.2 Genentech, Inc. Description and Business Overview
6.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio
6.4.5 Genentech, Inc. Recent Developments/Updates
6.5 Verseon Corp
6.5.1 Verseon Corp Company Information
6.5.2 Verseon Corp Description and Business Overview
6.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio
6.5.5 Verseon Corp Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Embolism Drug Industry Chain Analysis
7.2 Pulmonary Embolism Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Embolism Drug Production Mode & Process Analysis
7.4 Pulmonary Embolism Drug Sales and 麻豆原创ing
7.4.1 Pulmonary Embolism Drug Sales Channels
7.4.2 Pulmonary Embolism Drug Distributors
7.5 Pulmonary Embolism Drug Customer Analysis
8 Pulmonary Embolism Drug 麻豆原创 Dynamics
8.1 Pulmonary Embolism Drug Industry Trends
8.2 Pulmonary Embolism Drug 麻豆原创 Drivers
8.3 Pulmonary Embolism Drug 麻豆原创 Challenges
8.4 Pulmonary Embolism Drug 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Verseon Corp

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.